Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study

Table 2 Subgroup analysis according to serum ferritin level (n = 80)

Variables	Values	Ferritin (ng/mL)		P-value
		Low^a	High^b
		n = 45	n = 35
Age (years)	< 65 / ≥65	31/14	19/16	0.181
Gender	Female / Male	15/30	12/23	0.930
ECOG-PS	0–1 / 2	42/3	24/11	0.004
BMI (kg/m²)	< 23 / ≥23	23/22	21/14	0.430
Tumor Type	HCC / BTC or cHCC-CC	22/23	11/24	0.116
Previous anticancer therapy	No / Yes	11/34	14/21	0.136
Hb (g/dL)	Low^c / High^d	28/17	22/13	0.950
Total bilirubin (mg/dL)	≤1.2 / > 1.2	37/8	27/8	0.570
AST (IU/L)	< 40 / ≥40	24/21	13/22	0.150
ALT (IU/L)	< 40 / ≥40	27/18	19/16	0.610
γ-GT (IU/L)	≤66 / > 66	22/23	3/32	< 0.001
PT INR	≤1.16 / > 1.16	32/13	25/10	0.980
Albumin (g/dL)	< 3.5 / ≥3.5	7/38	6/29	0.850
WBC (×10³/μL)	< 10.0 / ≥10.0	43/2	27/8	0.013
CRP (mg/L)	< 10.0 / ≥10.0	31/14	9/26	< 0.001

ECOG-PS Eastern cooperative oncology group performance status, BMI body mass index, Hb hemoglobin, AST aspartate aminotransferase, ALT alanine aminotransferase, γ-GT gamma-glutamyl transpeptidase, PT INR prothrombin time international normalized ratio, WBC white blood cell, CRP c-reactive protein, HCC hepatocellular carcinoma, BTC biliary tract cancers, cHCC-CC combined hepatocellular-cholangiocarcinoma
^a female≤150 male≤200, ^b female> 150 male> 200, ^c female < 12.0 male < 13.0, ^d female ≥12.0 male ≥13.0

ISSN: 2662-7671